en
Scientific article
Open access
English

Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients

Published inAntimicrobial agents and chemotherapy, vol. 67, no. 4, e01732-22
Publication date2023-04-18
First online date2023-03-27
Abstract

We present two allogeneic hematopoietic cell transplantation recipients (HCTr) treated with pritelivir for acyclovir-resistant/refractory (r/r) HSV infection based on the expanded access program of the pritelivir manufacturer. Outpatient treatment with pritelivir was administered, with partial response by week 1 of treatment and complete response by week 4 of treatment in both patients. No adverse events were noted. Pritelivir appears to be an effective and safe option for the management of acyclovir-r/r HSV infections in highly immunocompromised patients in an outpatient setting.

eng
Keywords
  • Allogeneic hematopoietic cell transplant
  • Pritelivir
  • Resistant/refractory HSV infection
  • Humans
  • Antiviral Agents
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Salvage Therapy
  • Transplant Recipients
  • Herpes Simplex / drug therapy
  • Herpes Simplex / chemically induced
  • Acyclovir / therapeutic use
Citation (ISO format)
BOSETTI, Davide et al. Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients. In: Antimicrobial agents and chemotherapy, 2023, vol. 67, n° 4, p. e01732–22. doi: 10.1128/aac.01732-22
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal0066-4804
25views
19downloads

Technical informations

Creation09/27/2023 11:07:40 AM
First validation01/11/2024 7:52:04 AM
Update time01/11/2024 7:52:04 AM
Status update01/11/2024 7:52:04 AM
Last indexation05/06/2024 5:44:06 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack